Objective: The aim of this study was to clarify the role of N-terminal pro-brain natriuretic peptide, (NT-proBNP) in ibuprofen on preterm infants with patent ductus arteriosus (PDA).
Patients and methods: Preterm infants with PDA were enrolled in the present study. Patients were randomized into two groups: ibuprofen group received oral ibuprofen 10 mg/kg, followed by 5 mg/kg after 24 and 48 h, and the placebo group received the same volume of 5% glucose. PDA and NT-proBNP were detected during 24 hours, 3 and 7 days of age.
Results: The results indicated that babies who received oral ibuprofen had higher PDA closure at 7 days after treatment (p < 0.05). Significantly decrease of NT-proBNP was found in ibuprofen group than the placebo group at 3 and 7 days (all p < 0.05).
Conclusions: Collectively, the favorable effects of ibuprofen on PDA in premature infants maybe mediated in part by the reduction of NT-proBNP level.